Office of Health Economics Variations in Access to Orphan Drugs Across Europe
The Office of Health Economics have published a report which compares the availability of and access to orphan medicinal products (OMPs) in the UK (England, Scotland and Wales), France, Germany, Italy and Spain. The report analyses and quantifies the availability, access and the time between the granting of the EU authorisation and the decision to recommendation/reimbursement in each country.
